Akeso, Inc.: A Commercial-Stage Antibody Innovator Still Priced on Ivonescimab's Global Option Value

The qualitative-portrait label that fits best is company in transition with re-rating traits. The business has already crossed the fragile boundary from science project to commercial enterprise, but the stock has not yet crossed from option-heavy to cash-flow-anchored. That distinction is the whole investment case. If ivonescimab’s China data keep converting into approvals, guidelines, physician adoption, and credible ex-China replication, Akeso can graduate into a very different valuation framework over the next three to five years. If they do not, the stock can stay trapped between respectable commercial execution and a multiple that still expects much more.

2. Company vertical history

Akeso was born into a specific moment in Chinese biotechnology: local capital was becoming more willing to fund innovative drugs, but the ecosystem still lacked many homegrown platforms that could repeatedly discover differentiated antibodies rather than license “fast follow” assets from abroad. Akeso traces its operating history to March 2012, when Akeso Biopharma was founded in Zhongshan by Dr. Xia Yu and other co-founders. The prospectus describes Xia as the visionary key founder and ultimate controlling shareholder, while senior co-founders Baiyong Li, Maxwell Wang, and Peng Zhang covered scientific direction, discovery, clinical operations, and allied functions. The structure mattered. From the start, Akeso was built as a science-and-development shop, not as a thin shell around a single imported molecule.

The early problem Akeso tried to solve was not lack of antibodies in China. It was lack of differentiated ones. China already had reasons to worry that checkpoint inhibitors would become a crowded field with falling prices and limited differentiation. Akeso’s answer was to build an end-to-end discovery and development platform, later branded around the ACE platform and then expanded into a larger family of bispecific and multispecific technologies. In plain terms, the company tried to make itself valuable before any single product succeeded. That choice explains why Akeso’s later history shows both out-licensing and in-house commercialization: it was never only a licensing biotech, and never only a domestic commercial company either.

The first major external validation came early. In 2015, Akeso out-licensed its CTLA-4 antibody AK107 to Merck for consideration of up to US$200 million. That was not the company’s most valuable asset in hindsight, but it changed the firm’s trajectory. It signaled that a Chinese biotech could originate an antibody that a global major would take seriously, and it gave Akeso both credibility and capital to scale its platform. In a company history shaped by repeated attempts to persuade capital markets that China-originated science could travel, the Merck deal was the first proof point.

The next decisive node was the Hong Kong IPO. Akeso listed on the HKEX in April 2020 at HK$16.18 per share. This was the story capital markets first bought: a platform biotech with a broad antibody pipeline, a first-mover angle in bispecifics, and enough financing history to sustain aggressive R&D. The IPO was heavily subscribed, but the company that listed was still fundamentally a development-stage issuer. It had science, financing, and promise. It did not yet have the commercial proof that would come later.

Akeso’s post-listing history can be divided into four stages.

The first stage, from founding through roughly 2020, was platform construction and scientific validation. The key driver was capability-building: antibody discovery, translational work, and a pipeline broad enough to convince partners and IPO investors that Akeso was more than a one-product gamble. The financial signature of this stage was predictable for a young biotech: low revenue, heavy losses, operating cash burn, and financing-led balance-sheet growth. Akeso’s 2020 annual report showed net cash used in operating activities of RMB617.8 million. That was not a bug; it was the cost of building the machine.

The second stage, roughly 2021 to 2022, was the first commercial transition. Penpulimab was approved in China in 2021, while cadonilimab gained approval in 2022 for recurrent or metastatic cervical cancer, becoming one of the company’s first major commercial oncology products. Akeso’s 2022 sales jumped to RMB1.10 billion, with cadonilimab contributing RMB546.3 million in its first six months and penpulimab contributing RMB558.1 million. This stage mattered because it proved Akeso could do more than generate trial readouts. It could launch, get reimbursed, and sell. But profitability still did not follow in a straight line. The economics of a launch-heavy biotech meant high commercial spend and an ongoing R&D burden.

The third stage, 2023 to 2024, was the licensing-and-ivonescimab re-rating phase. Summit licensed ivonescimab in late 2022, and the transaction closed in early 2023 with US$500 million upfront, of which Summit paid US$474.9 million in cash plus 10 million Summit shares in lieu of US$25.1 million in cash. Additional milestones under the original deal and later expansion could reach into the billions, with low double-digit royalties on net sales. That one deal transformed Akeso’s 2023 reported numbers: revenue rose to RMB4.53 billion and operating cash flow swung positive to RMB2.47 billion, not because the underlying commercial franchise had suddenly matured, but because a large licensing payment flowed through the accounts. Investors had to decide whether to treat 2023 as a new normal or a giant accounting spike. The correct answer was the latter.

The fourth stage, from 2024 into 2026, is the stage Akeso is in now: science translated into commercial acceleration, but valuation dominated by global readthrough. Ivonescimab won China approval in May 2024 in EGFR-mutated non-squamous NSCLC after TKI progression, then was approved again in 2025 as monotherapy for first-line PD-L1-positive NSCLC based on HARMONi-2. Cadonilimab expanded into gastric cancer in 2024 and first-line cervical cancer in 2025. Penpulimab, through Akeso, won FDA approval in 2025 for nasopharyngeal carcinoma. In 2025, Akeso’s commercial sales rose to RMB3.03 billion, NRDL coverage broadened, and the company looked increasingly like a real commercial oncology house. Yet the stock still traded most violently on ivonescimab’s trial outputs rather than on cadonilimab prescription trends or penpulimab’s niche US approval. That tells you what investors think matters most.

Several key nodes still shape Akeso today.

The first was the 2015 Merck deal. In hindsight, it was underrated in public markets because it did not itself create today’s flagship asset. But institutionally it changed Akeso’s fate. It told management, employees, and later investors that the platform could produce globally interesting science. That matters in biotech because confidence compounds inside the organization long before it compounds in revenue.

The second was the 2022 Summit transaction. This one was genuinely fate-changing. It did four things at once: it validated ivonescimab externally, financed Akeso heavily without forcing it to surrender China rights, created an ex-China public-market mirror in Summit, and gave the market a benchmark for global optionality. Deals that shift financing, validation, and valuation all at once are rare. This was one of them.

The third was HARMONi-2 in 2024. A head-to-head Phase III win against pembrolizumab in PD-L1-positive NSCLC changed the tone of the ivonescimab conversation. It moved Akeso from “China biotech with promising mechanism” toward “company whose data have to be discussed against global standards.” That node was not yet enough to settle the stock’s fate, but it was enough to begin the re-rating.

The fourth was the capital-raising sequence. Akeso placed 24.8 million shares in March 2024 at HK$47.65, 31.7 million shares in October 2024 at HK$61.28, and 23.55 million primary placing shares in August 2025 at HK$149.54. Those placements diluted shareholders, but they were also a blunt market signal: management was monetizing a richer narrative to extend runway and accelerate R&D and commercialization. In a biotech, dilution can be destructive or intelligent. These raises look closer to intelligent financing, though not costless, because they were executed into strength and pushed financing risk further out.

The fifth was HARMONi-3 versus HARMONi-6. This pair revealed the market’s current skepticism structure. When Summit disclosed that the squamous cohort interim PFS analysis in HARMONi-3 did not reach statistical significance, the stock reaction was harsh. When Akeso later showed strong OS data from HARMONi-6 in China and landed an ASCO plenary slot, that repaired scientific enthusiasm but did not fully silence transferability questions. This sequence still shapes the stock today. HARMONi-6 improved the science case. HARMONi-3 kept the valuation debate open.

3. Financial vertical review

Akeso’s financial statements are most readable when separated into three layers: product sales, license swings, and platform-cost burden. If those layers are collapsed into one headline line, the business looks more volatile than it really is. If they are separated, the pattern is clearer: commercial revenue is growing fast; licensing is episodic and distorting; the organization still spends like a company trying to win several future markets, not just harvest the current one.

Key financial trend table

Sources and notes: 2023–2025 annual-report data come from Akeso filings; 2022 commercial sales and cash-on-hand summary come from Akeso’s 2022 results release. 2024 year-end cash in the table uses the 2024 annual report balance-sheet and liquidity discussion. † 2022 result-release summary. ‡ 2024 cash, cash equivalents, time deposits and financial products from 2024 annual report liquidity section.

The business reason behind those numbers is straightforward. Revenue growth since 2022 has come increasingly from commercialization rather than from collaboration accounting. In 2025, commercial sales were 99% of reported revenue because license income fell sharply to roughly RMB23 million after the huge Summit-linked recognition in 2023 and residual contribution in 2024. That is healthier than it looks at first glance. It means Akeso is becoming more dependent on its own products and less dependent on one-off deal accounting. The market can no longer excuse poor cash conversion by pointing to “development-stage volatility” alone.

Gross profits improved with scale, but the more revealing lines are below gross profit. The 2025 cost of sales rose as ivonescimab and cadonilimab volumes increased. At the same time, Akeso continued to spend heavily on R&D and sales infrastructure. This is the normal income statement of a commercializing biotech: R&D does not fall because the company has too many shots still in flight, and selling expense rises because launch success requires field force, education, reimbursement work, and hospital penetration. Akeso’s 2025 loss therefore does not mean the products failed. It means the company is still paying for the present and the future at the same time.

Cash conversion is the area that matters most for capital preservation. Akeso’s operating cash flow was negative in 2020, negative again in 2022, strongly positive in 2023 because of licensing cash, then negative in both 2024 and 2025. Over that span, accounting earnings and cash earnings only matched in the one year dominated by milestone economics. That is why the right discipline is to treat 2023 as non-recurring for cash-flow valuation purposes. The company is not yet a durable free-cash-flow generator. It is a well-financed commercial/pipeline hybrid.

The balance sheet is stronger than many investors may assume from the loss line. At 2025 year-end, current assets were RMB11.28 billion, including RMB9.17 billion in cash, cash equivalents, time deposits, and financial products. Current liabilities were RMB2.20 billion, and long-term loans were RMB3.95 billion. Trade receivables stood at RMB1.02 billion, mostly within three months, while inventories were RMB931.6 million. This is not a distressed biotech scrambling for six months of runway. It is a company that can absorb setbacks, though not indefinitely if a large part of the pipeline stalls.

Returns on capital are still a poor guide here because the numerator is being distorted by licensing and launch-cycle effects. In 2023, profitability surged on the Summit deal; in 2024 and 2025, losses returned as the company leaned into commercialization and late-stage development. I would not call Akeso’s current ROIC structurally weak, but I would not call it strong either. The metric is simply not yet stable enough to anchor valuation. In this phase, pipeline quality, cash runway, launch traction, and regulatory conversion matter more than a point-in-time ROE.

4. Price and valuation history

Akeso’s price history has moved through three broad valuation regimes.

The first regime was the post-IPO platform-biotech phase. The market valued Akeso mainly as a pipeline and platform name: a company with many shots on goal but few hard commercial proofs. In that world, the multiple investors paid was tied to risk appetite for Hong Kong biotech more than to near-term sales. IPO pricing at HK$16.18 captured this phase.

The second regime was the commercialization-and-licensing regime. As cadonilimab and penpulimab entered the market and the Summit transaction arrived, Akeso stopped being a pure pre-revenue concept. The 2023 accounts were dramatic on paper because the licensing economics flowed through reported revenue and profit. Market participants then had to reclassify Akeso: not just a science platform, not yet a mature cash generator, but a hybrid with real product sales plus landmark licensing credibility. That combination expanded the valuation center.

The third regime is the ivonescimab-supercycle regime. In this phase, the stock trades more like a referendum on one asset than on the consolidated accounts. By August 2025, the shares had reached a 52-week high of HK$179.00. By late June 2026 they were around HK$87.5, near the 52-week lows around HK$80–83. The collapse from the high is not the market abandoning Akeso’s science. It is the market moving from “global replacement of IO 1.0 may be near” toward “show me the global conversion, not just the China excellence.”

On simple multiples, current valuation is still rich relative to current fundamentals. Using 2025 revenue of RMB3.06 billion and an RMB/HKD rate near 1.1573, Akeso’s 2025 revenue translates to roughly HK$3.54 billion. Against a market capitalization near HK$78.8 billion, that is about 22 times trailing sales. The EV/Sales figure is only modestly lower. Innovent, by contrast, is around 8.8 times trailing sales on FY2025 revenue and a market cap around HK$132 billion, while BeOne is about 5.4 times sales on FY2025 revenue and a US$29.3 billion market cap. The market is not pricing Akeso as a normal Chinese commercial biotech. It is pricing a future-option asset whose current sales are merely the floor.

That is why Akeso’s valuation center shifted. The business quality improved, yes. But market preference also changed. Investors were doing more than rewarding actual sales and approvals. They were pre-spending on the possibility that ivonescimab could become one of the few China-originated oncology drugs to alter global treatment frameworks rather than fill domestic niches. Whether that premium was deserved in 2025 is less important now than whether enough of it remains in the shares even after the drawdown. I think some of it does.

5. Business model and moat

Akeso’s business model now has three engines.

The first engine is direct product commercialization in China. By 2025 the company had seven products in the commercial stage, with cadonilimab and ivonescimab at the center of the oncology story and non-oncology assets such as ebronucimab and ebdarokimab helping diversify the base. Product revenue is still concentrated, but there is a real portfolio now rather than a single-brand launch. The commercial machine matters because physician adoption, reimbursement, and manufacturing reliability determine how much of Akeso’s clinical value converts into actual cash generation.

The second engine is licensing and partnership economics. The Summit deal covers the United States, Canada, Europe, Japan, and, after the 2024 amendment, Latin America, the Middle East, and Africa. Akeso remains eligible for substantial development, regulatory, and commercial milestones plus low double-digit royalties on net sales, and it continues to supply ivonescimab into the licensed territories. This engine is economically powerful because it lets Akeso participate in global expansion without funding the whole ex-China machine itself. It is also volatile because milestone recognition and royalty timing are inherently uneven.

The third engine is platform monetization. Akeso’s ACE platform and related bispecific/multispecific technologies are concrete: they are the reason partners such as Merck and Summit entered the picture in the first place. The company describes a portfolio of over 50 programs and 94,000L of production capacity, which tells you management is building for repeatability rather than for one hero asset. In biotech, repeatability is the closest thing to a scale moat.

The cost structure follows from that model. Variable costs live in manufacturing, distribution, and commercialization. Fixed or semi-fixed costs live in R&D teams, clinical infrastructure, platform maintenance, and the overhead required to run a regulated biologics organization. Akeso will have operating leverage eventually, but it does not yet enjoy it cleanly, because new approvals trigger new spend almost as quickly as they trigger new revenue. When revenue falls short or licencing income disappears, profit can swing quickly because the R&D base does not shrink at the same speed. That is why Akeso’s earnings look jagged and why cash-flow discipline matters more than non-IFRS storytelling.

The real moat has three parts.

The first is scientific track record. Many biotech managements talk about platforms; fewer can point to multiple approved products, multiple partners, and head-to-head data that force the rest of the field to react. Akeso can. The Merck and Summit transactions, the approvals of cadonilimab and ivonescimab in China, the FDA approval of penpulimab, and the ASCO plenary selection for HARMONi-6 all say the same thing: the company’s science deserves to be discussed globally. That is a real moat because it helps with talent, partnerships, capital access, and investigator mindshare.

The second is speed of internal translation from discovery to clinic to approval. Akeso does not merely invent antibodies; it advances them through trials, filings, manufacturing, and market access. Companies that can repeatedly move programs across those stages are rarer than companies that can publish preclinical figures. Akeso’s seven commercial-stage products and broad late-stage pipeline show that its discovery platform is wired to an execution system.

The third is manufacturing and China commercialization infrastructure. At 94,000L capacity, including 55,000L operating capacity at the Greater Bay Area Technology Park, Akeso has moved beyond the “virtual biotech” model. In antibody drugs, manufacturing speed, quality assurance, and supply reliability matter to both domestic launches and partner supply. This is not as glamorous as a plenary abstract, but it is part of why partnerships and self-commercialization can coexist.

There are also moats Akeso does not really have yet. Brand is still product-brand, not company-brand. Switching costs for oncologists can be powerful once guidelines and reimbursement lock in, but they are weaker where standards are still fluid. Network effects do not apply in the classic software sense. So the right way to describe Akeso’s moat is validated innovation plus execution infrastructure, not untouchable platform dominance. That is strong, but it can still erode if the science loses its comparative edge.

Governance is mostly acceptable, with some features worth noting. Dr. Xia remains chairwoman and chief executive officer, so the company combines the two roles. The board explicitly says this is meant to provide strong and consistent leadership. That can be efficient in founder-led biotech, but it also means investors are placing meaningful trust in one central figure. Akeso uses equity incentives, and the 2025 annual report showed material share-option availability under the scheme limits. Ernst & Young remains the external auditor. I did not find evidence in the materials reviewed of major accounting scandal, fraud allegations, or destabilizing auditor turnover. The principal governance discount is founder centrality, not a broken control environment.

6. Industry and cycle

Akeso sits at the intersection of two industry structures. One is the Chinese innovative-biologics market, where commercialization can be scaled rapidly once reimbursement is won but pricing pressure can be brutal when products look interchangeable. The other is global immuno-oncology, where the economic prize is huge but the bar for evidence, design, and regulatory trust is much higher. Akeso’s importance comes from trying to connect these two worlds with one platform and one flagship asset.

China’s current antibody market rewards differentiation more than presence. The me-too PD-1 era compressed value because many developers could offer the same broad mechanism with limited clinical distinction. Akeso’s rise is partly a reaction against that commoditization. Cadonilimab and ivonescimab are valuable because they go beyond being more PD-1 antibodies; they aim to improve efficacy by marrying targets inside one molecule. In industry terms, Akeso is taking profit from the part of the immuno-oncology pool where physicians and payers still see a reason to choose one product over another, even in a system that pushes hard on affordability.

This industry is driven most by a technology-iteration cycle and a policy/reimbursement cycle, with less exposure to classic macro cyclicality than industrial or consumer sectors. If Akeso’s trial data keep outperforming older standards, the company benefits from technology substitution: IO 2.0 displacing IO 1.0. If reimbursement broadens and guideline inclusion deepens, the company also benefits from policy transmission. The fragility is obvious too. When trials disappoint or transferability questions arise, the valuation can deflate before domestic sales have time to catch up.

Regulation is the main bridge between Akeso’s science and its equity value, not background noise. China’s NMPA approvals turned ivonescimab and cadonilimab into commercial franchises. The U.S. FDA’s acceptance of Summit’s ivonescimab BLA set a November 14, 2026 PDUFA date for the EGFR-mutated NSCLC setting. That one date matters far beyond one indication because it is also a referendum on how regulators outside China view the underlying data package and the asset’s credibility.

Geopolitics exists, but it is not yet the decisive risk many might assume. The Summit structure actually reduces one layer of direct geopolitical friction because it creates a U.S.-listed partner responsible for the ex-China push. The harder issue is quieter: whether regulators, physicians, and investors apply a discount to China-conducted or China-heavy data even when the results are strong. This is an evidence-translation problem, not a tariff one. It can affect approval timelines, label breadth, commercial credibility, and therefore valuation.

7. Horizontal competitor analysis

Akeso’s true peer set is mixed. No single listed company matches it perfectly because Akeso is at once a China commercial-stage biotech, a bispecific-platform originator, and the source company behind a globally traded partnered asset. The most useful comparison set is therefore a group portrait rather than a one-formula multiple table: Innovent as the Chinese commercial biologics peer, BeOne as the Chinese-origin global oncology benchmark, Summit as the ex-China mirror asset, BioNTech as the closest large-cap PD-L1/VEGF-style mechanism peer through BNT327, and Merck as the incumbent standard that defines what “replacement” would really mean.

Selected peer snapshot

Sources: Akeso 2025 annual report and market data; Innovent FY2025 results and market data; BeOne FY2025 revenue and market data; BioNTech FY2025 results and market data; Summit market data and filings. Akeso and Innovent trailing sales multiples in this table are approximate calculations using market caps in quote currency and FY2025 revenue translated where needed.

The business reason behind the valuation differences is revealing. Innovent is already a bigger domestic commercial machine. Investors can model product sales, cost leverage, and China execution with fewer heroic assumptions. Akeso, by comparison, still commands a richer sales multiple because investors are capitalizing the upside of ivonescimab more aggressively than they are capitalizing Akeso’s existing portfolio. In plain words, Innovent is easier to underwrite; Akeso is easier to dream about.

BeOne shows the other end of the spectrum. It has already built what Akeso has not: a global commercial oncology organization, anchored by BRUKINSA and supported by a large pipeline. That comes with scale and credibility. But it also means BeOne’s valuation tells you more about global oncology commercialization than about a single high-octane mechanism bet. Akeso’s discount in absolute size to BeOne is justified; its premium on current sales is explained by optionality, not by operating maturity.

Summit is less a peer than a diagnostic instrument. If investors want to isolate ex-China ivonescimab exposure, they often look there first. Summit has no meaningful diversified revenue base to soften the blow of any ivonescimab disappointment, while Akeso at least owns the China franchise and wider pipeline. That means Summit is the higher-beta mirror and Akeso the broader, but still highly correlated, originator. When Summit falls on trial-design or subgroup concerns, Akeso is reminded that part of its own valuation rests on a market story it cannot fully control.

BioNTech’s BNT327 is the competitor that matters most strategically. The target pairing differs from ivonescimab’s (PD-L1/VEGF-A rather than PD-1/VEGF), but economically and narratively it lives in the same future: the attempt to create the next immuno-oncology backbone by fusing checkpoint inhibition with anti-angiogenesis. BioNTech’s partnership with Bristol Myers Squibb, including US$1.5 billion upfront and a total potential value above US$11 billion, tells you this race is now one of the most valuable battles in oncology. Akeso’s strength is that it already has striking clinical data and China approvals. BioNTech’s strength is that it has a deeper global partner apparatus and a capital structure far less dependent on one asset’s near-term monetization.

Merck remains the benchmark, not because Akeso resembles it, but because pembrolizumab is still the incumbent standard many first-line lung-cancer studies must beat or displace. Akeso’s historical out-license to Merck and ivonescimab’s head-to-head relevance against pembrolizumab make Merck a useful reference for what true global disruption would mean. Replacing or even partially displacing Keytruda goes beyond a scientific achievement. It is the level of commercial proof required for Akeso’s most optimistic narrative to come true.

In ecological-niche terms, Akeso is a challenger with unusually high scientific leverage. It is not the incumbent scale leader; it is the company trying to take profit from the gap between older checkpoint standards and the next generation of dual-mechanism immuno-oncology. That niche gets stronger if technology substitution dominates. It gets weaker if regulators and global physicians decide that regional trial wins are not enough.

8. Current fundamentals and bull-bear divergence

Akeso does not report quarterly in the same way a U.S. biotech does, so the best available “last four quarters” picture is the full-year 2025 annual report plus 2026 clinical and regulatory updates. That picture shows a company whose commercial engine is genuinely expanding. Revenue in 2025 rose 43.9% to RMB3.06 billion; commercial sales rose 51.5% to RMB3.03 billion; 2025 growth was driven by NRDL inclusion for cadonilimab and ivonescimab and by newly approved high-incidence first-line indications. This is real business progress, not an investor narrative.

Yet the same period also showed why the market is still trading the story more than the statement of cash flows. Operating cash flow was negative RMB947.6 million in 2025. Selling expense remained heavy as the company pushed launches, and R&D remained substantial. Management effectively chose to press the advantage while the science was strong. That can be the right decision, but it means the nearest-term earnings model remains easy to disappoint.

What the market is trading right now is the gap between HARMONi-6 jubilation and HARMONi-3 caution, not 2025 sales. The current share price mainly reflects four stacked expectations: that ivonescimab’s China data continue to impress; that ex-China approval odds improve into the November 2026 FDA decision in EGFR-mutated NSCLC; that broader first-line lung-cancer positioning remains intact despite the HARMONi-3 interim wobble; and that Akeso’s domestic commercial base keeps compounding while investors wait. There are fundamentals behind that narrative, but this is still a narrative-dominant stock.

The bull case rests on concrete evidence. First, ivonescimab has now generated multiple headline-grade data points: China approval in EGFR-mutated post-TKI NSCLC, positive HARMONi-2 against pembrolizumab, and significant OS benefit in HARMONi-6 versus tislelizumab plus chemotherapy. Second, Akeso’s commercial sales are no longer token. Third, the Summit structure lets Akeso participate in ex-China upside without carrying all ex-China development and commercialization spending. Fourth, the company still has a broader platform and follow-on pipeline beyond the flagship.

The bear case also rests on concrete evidence. First, the stock’s sales multiple still assumes a great deal of future success not visible in current cash flow. Second, 2023’s licensing spike can mislead investors about normalized profitability. Third, HARMONi-3 reminded the market that global replication is not automatic. Fourth, some analysts still question subgroup consistency and the degree to which China-only data can be read through to Western regulatory or commercial settings. Fifth, Akeso has used equity financing repeatedly during the rerating, which is sensible but still dilutive.

9. Valuation analysis

9.1 Historical valuation

Historically, Akeso’s valuation has swung with the likelihood that the market assigns to flagship-asset globality. Today’s price is far below the 2025 peak, but current valuation is still rich against present-day fundamentals. At roughly 22 times trailing sales, the stock is less expensive than peak narrative, which is not the same as cheap because it fell. Relative to its own recent history, it is off the froth; relative to current cash generation, it still embeds meaningful future success.

9.2 Peer valuation

Akeso trades on a much higher sales multiple than larger and more established peers such as Innovent and BeOne. That premium is partly justified because Akeso owns a more explosive single-asset option in ivonescimab. But it is also dangerous because the same premium can unwind if global readthrough weakens. Investors should not conclude that Akeso is cheap just because it is below the old peak or because Summit and other mechanism peers sometimes trade at extreme levels. Akeso still carries a large narrative premium.

9.3 Absolute valuation

9.3.0 Cash-flow passthrough

Over the last several years, Akeso’s operating-cash-flow-to-net-income relationship has been dominated by one-off collaboration economics. Operating cash flow was negative in 2020, negative in 2022, strongly positive in 2023 when the Summit economics hit, then negative in 2024 and 2025. That pattern says accounting earnings are not a reliable valuation base yet. Maintenance capex is also hard to isolate cleanly because Akeso is still building out manufacturing and commercial infrastructure; the majority of recent physical capex appears growth-oriented, though a reasonable maintenance assumption for an existing biologics plant base would still be material. On either an owner-earnings basis or an operating-cash-flow basis, present free cash flow is negative. The practical implication is clear: Akeso should be valued on a sum-of-the-parts or risk-adjusted pipeline basis, not on headline P/E.

9.3.1 Scenario table

This scenario analysis is part of a research framework, not investment advice.

Sources for inputs: Akeso annual reports, Summit licensing disclosures, current market data, and peer/reference transactions around mechanism-adjacent assets. The ranges are my scenario-based synthesis, not company guidance.

The logic behind the conservative case is that Akeso’s existing portfolio and China rights still matter even if ex-China expectations fade. The logic behind the base case is that current valuation can be justified only if the company continues converting clinical validation into approvals and adoption without a major break in the global narrative. The optimistic case assumes that ivonescimab’s ex-China economics start looking more like a global backbone opportunity than a regional success story.

9.4 Expectation-gap analysis

The market is currently pricing more than continued China commercial growth. It is pricing a serious chance that ivonescimab becomes globally important. The expectation gap therefore sits in three places: the quality of global readthrough from China data, the pace and breadth of ex-China regulatory conversion, and the extent to which Akeso’s domestic commercial business can stand on its own if the global thesis takes longer. The next major events investors will care about most are the FDA review path, incremental global-trial updates, and whether future domestic sales disclosures prove that ivonescimab and cadonilimab are becoming durable, broad-based franchises rather than event-driven launch stories.

9.5 Margin-of-safety recheck

At HK$87.5, the current price is above the value implied by the lower end of the conservative scenario and near the lower-middle of the base case. That means the margin of safety is not zero, but it is not generous either. The most fragile assumption in the base case is ex-China conversion of ivonescimab into a broadly monetizable asset, not China launch momentum. If that assumption is cut materially, the base-case value slides much closer to the current price. Using the China 10-year government bond yield around 1.74% as a rough low-risk comparison, Akeso can still clear that hurdle in the base and optimistic scenarios, but not with a wide comfort cushion in the conservative one. My margin-of-safety sufficiency verdict is not obvious.

10. Risk analysis

The biggest permanent-loss risk is the destruction of the ivonescimab premium before the rest of Akeso’s commercial business is large enough to carry the valuation on its own. This goes well beyond ordinary biotech volatility. Probability medium, impact high. The observable indicators are straightforward: negative or weakly translatable global-trial updates, FDA delays or more restrictive-than-expected labeling, and sustained market skepticism toward China-only evidence. The transmission path runs from reduced royalty and milestone expectations to multiple compression on the entire stock.

The second major risk is commercialization under-delivery in China despite good science. Probability medium, impact high. The indicator set is slower commercial-sales growth, weaker reimbursement leverage, persistent negative operating cash flow, or a sales-force build that does not generate operating leverage. A lot of Akeso’s current downside protection depends on the domestic commercial base becoming steadily more valuable. If that base disappoints while the flagship still consumes management attention, investors lose both the floor and part of the option.

The third risk is dilution and capital-allocation slippage. Probability medium, impact medium-to-high. Akeso has sensibly raised capital into strength, but the pattern is still real: March 2024, October 2024, and August 2025 placements all expanded the share count. If future setbacks force capital raising at weaker prices, the shareholder economics change sharply. In biotech, financing flexibility is a strength until it is exercised from a position of weakness.

The fourth risk is competitive leapfrogging in next-generation IO. Probability medium, impact medium-to-high. BioNTech/BMS’s BNT327 and other PD-(L)1/VEGF-style approaches show that Akeso is not alone in trying to define IO’s next backbone. If competitors generate cleaner global data, better convenience, or better partnership economics, Akeso’s scientific lead may narrow even if ivonescimab remains a good drug. In premium-multiple stocks, relative leadership matters almost as much as absolute progress.

The fifth risk is founder concentration. Probability low-to-medium, impact medium. Dr. Xia’s central role has likely helped Akeso move quickly, but it also raises key-person exposure. In founder-led science companies, execution, hiring, and partnering often become unusually sensitive to one executive nucleus. There is no immediate red flag here; the point is simply that power is concentrated and investors should not pretend otherwise.

11. Catalysts and tracking indicators

Positive catalysts are easy to name because the market already tells you what it cares about. FDA progress on ivonescimab in the EGFR-mutated NSCLC setting would reduce one layer of ex-China uncertainty. Additional globally relevant Phase III evidence, especially evidence that resolves the HARMONi-3 overhang, would matter even more. Domestically, another year of 30%-plus commercial-sales growth with better operating cash conversion would prove that Akeso is not merely renting a premium multiple from its flagship asset.

Negative catalysts are the mirror image. Any sign that ex-China regulators are less persuaded than investors expected; any further awkward readthrough between China-led wins and global-trial ambiguity; and any stretch of domestic sales growth that fails to dent cash burn would all hit the shares. Large secondary financing at a weak price would be another clear negative because it would say the balance-sheet surplus was less durable than it looked.

Tracking dashboard

These are the right indicators because together they test all three pillars of the stock: the domestic floor, the global option, and the financing bridge between them. Most investors will over-focus on ASCO-style headlines and under-focus on operating cash flow and share issuance. For Akeso, both matter. A premium-multiple biotech becomes safer when science and cash begin telling the same story.

12. Cross-synthesis summary

Vertically, the capability Akeso has genuinely proven is not just invention. It is the ability to originate differentiated antibody programs, carry them through development, and then choose rationally between self-commercialization and partnership. That sounds simple, but it is the hardest combination to achieve in biotech. Plenty of firms discover. Fewer launch. Fewer still produce assets good enough that global partners will write very large checks while leaving meaningful territorial economics behind. Akeso has done all three. The Merck deal in 2015 was the first proof of that capability, the Summit deal in 2022–2023 was the second, and the 2024–2026 ivonescimab readouts turned that capability from a historical curiosity into the center of the equity story.

Its earlier success came from several sources at once. There was a favorable era backdrop: Chinese biotech capital deepened, Hong Kong listing rules created a venue for pre-profit innovation names, and domestic regulators became more open to innovation. But Akeso’s progress was not simply an era trade. The company’s repeated out-licensing and approval record suggest real management and scientific skill. A lucky company might pull off one good program. Akeso has pulled off enough distinct wins that luck is not the main explanation anymore.

Those success factors are still present, but not in equal strength. The platform is still there. The management team is still there. The domestic commercialization machine is larger than it was. The capital markets are less forgiving than they were at the 2025 peak. And the easiest part of the ivonescimab rerating, convincing investors that the signal is real, is mostly done. The hard part now is converting signal into scope: scope of label, scope of geographic transfer, scope of commercial use, and scope of durable free cash flow.

Horizontally, Akeso’s real advantage over peers is that it owns a rare combination: first-class China data, a live China commercial engine, and a partner-funded ex-China pathway. Innovent has more commercial scale today. BeOne has more global infrastructure. BioNTech has more financial strength and a heavyweight global ally. Summit has a purer ex-China exposure. Akeso alone gives an investor one security that contains a domestically monetizing business, the originator rights on the flagship, a broad platform, and still-open global optionality. That is why the stock can never be valued on simple China-product multiples alone. It is also why the shares can stay expensive longer than valuation purists expect.

The problem is that today’s valuation is still partly rewarding future success before it is fully earned. Current sales and current cash flow do not justify the whole market cap on their own. Some of that cap is the market paying in advance for a future in which ivonescimab becomes far larger across China and begins paying Akeso materially outside China as well. I think that future is plausible. I do not think the current price offers a large enough discount to its fragility. The market is most likely misjudging the speed of the transition from clinical glory to financially visible global monetization. Biotech investors often assume that once data prove superiority, value follows in a roughly straight line. In reality, value arrives in a staircase: approval, label wording, reimbursement, guideline uptake, field-force execution, duration, combinations, and only later clean cash flow. Akeso is still climbing those steps.

For the next year, the single most important variable is ivonescimab’s regulatory and clinical readthrough outside the narrowest domestic frame, especially into the U.S. review path and additional global-trial interpretation. For the next three years, what matters most is whether domestic product sales and ex-China economics start reinforcing one another rather than making the stock choose between them. For the next five years, the decisive test is platform repeatability: whether Akeso becomes a one-asset legend or a multi-asset institution. If the latter happens, today’s debate about whether the stock is “too dependent on one molecule” will look dated. If not, investors may look back and realize they paid a platform multiple for a flagship franchise.

Akeso becomes a better investment under three conditions. The first is price: a materially lower entry, around the high-50s to mid-60s HKD zone, would create a much better margin of safety against the conservative scenario. The second is evidence: clean progress on the FDA path and more globally persuasive ivonescimab data would justify the premium with less hand-waving. The third is cash proof: an operating-cash-flow trajectory that visibly improves as commercial sales rise would let investors give the company credit not just for science, but for economic conversion. I would overturn a cautious judgment only if those conditions improve substantially, or if the market price offers the science at a more forgiving valuation.

12.1 Bull and bear reasons

Bull reasons:

• Ivonescimab has produced multiple high-grade efficacy signals, culminating in HARMONi-6 overall-survival benefit with HR 0.66 and ASCO 2026 plenary visibility.
• Akeso now has a real commercial base, with 2025 commercial sales up 51.5% to RMB3.03 billion, reducing dependence on licensing spikes.
• The Summit agreement lets Akeso retain China rights while still participating in ex-China upside through milestones, royalties, and supply revenue.
• The platform has already proven repeatability beyond one asset through multiple approvals, a Merck out-license, and FDA approval for penpulimab.
• The balance sheet gives the company time, with RMB9.17 billion of cash and related financial assets at year-end 2025.

Bear reasons:

• At about 22 times trailing sales, the stock still embeds large future success that current cash generation does not yet support.
• 2023 profitability was heavily distorted by the Summit transaction, so historical earnings power is easy to overstate.
• HARMONi-3’s interim PFS miss in the squamous cohort showed that global replication and trial-design execution are not automatic.
• Analyst concern about age subgroups and China-only evidence means headline-positive results do not translate one-for-one into ex-China value.
• Repeated placements in 2024 and 2025 were rational, but they still prove that Akeso remains a capital-consuming business rather than a self-funding one.

12.2 Pre-mortem

Script one: by late 2027, Summit’s ex-China ivonescimab path runs into a regulatory or clinical wall. The November 2026 FDA decision is delayed or narrower than expected, HARMONi-3 fails to give the global corroboration investors want, and the market starts valuing Akeso mostly on its domestic commercial franchise. Commercial sales still grow, but not enough to justify a premium multiple. The shares derate from a future-option framework toward a China-commercial-biotech framework, and the stock could plausibly lose 40%–50% from current levels through both lower expected ex-China economics and outright multiple compression.

Script two: the science remains good, but the economics lag. Through 2027 or 2028, cadonilimab and ivonescimab keep expanding in China, yet selling expense, R&D expense, and manufacturing buildout keep operating cash flow negative. Investors stop arguing over whether ivonescimab can beat older standards and start asking why the company still has to finance growth externally. Another capital raise lands at a weaker price, and the stock halves not because the drug failed, but because the market no longer trusts the path from good data to per-share value.

12.3 Final research conclusion

Akeso is a serious biopharmaceutical company, not a laboratory fantasy. It has already proven it can discover important antibodies, win approvals, sign large global partnerships, and build a meaningful domestic commercial business. That deserves respect. What the current stock price asks investors to do, however, is to pay not merely for what Akeso has built, but for a sizable slice of what ivonescimab might still become. That is the tension in the name.

At today’s price, I think Akeso is ownable only if an investor is consciously paying for optionality and accepts that the margin of safety is limited. The business quality is better than many narrative names, but the valuation is not yet generous enough to absorb a major disappointment in ex-China readthrough. What worries me most is the gap between excellent data and the slower, messier work of turning those data into global regulatory acceptance and clean per-share cash economics, not the science itself. What would change my mind in a more constructive direction is either a cheaper entry price or clearer proof that the ex-China pathway is becoming less speculative and the domestic business more cash generative.

【Company-profile scores】

• Fundamental quality: medium
• Growth: high
• Moat: medium
• Financial soundness: strong
• Management credibility: medium
• Valuation attractiveness: low
• Risk level: high
• Suitable investor type: long-term growth

【Investment rating】

• Rating: Hold
• One-line thesis: Akeso owns unusually strong science and a real China commercial base, but the current price still pre-pays too much of ivonescimab’s global upside.
• Three price signals:
  • Ideal buy price: 【Ideal Buy Price】58–64 HKD Basis: at least a 20% discount to the lower half of the conservative intrinsic-value range of HK$72–80 per share.
  • Acceptable hold price: 75–117 HKD
  • Clearly overvalued price: 130–145 HKD
• Current-price classification: acceptable hold
• Whether to wait for a better price: yes. A move into roughly HK$58–64 with no material deterioration in ivonescimab’s regulatory path or domestic commercial growth would create a much better entry. The opportunity cost of waiting is missing a sharper rerating if FDA/global evidence improves faster than expected.
• Target holding horizon: 3–5 years
• Expected annualized return: conservative about -4% to -6%; base about 1% to 5%; optimistic about 11% to 14%
• Max-loss risk: roughly 40%–50%, triggered by a break in the ex-China ivonescimab thesis combined with continuing cash burn and multiple compression
• Reassessment-trigger signals:
  • if ex-China ivonescimab regulatory progress materially slips from the current November 2026 FDA target path
  • if future Phase III/global data fail to replicate the strength implied by China readouts
  • if annual commercial-sales growth drops below 20% without offsetting margin improvement
  • if operating cash outflow remains near or worse than RMB1 billion despite rising sales
  • if Akeso returns to large-scale equity financing without a correspondingly stronger value inflection

【Valuation Range】

• current: 87.5 (close as of 2026-06-23)
• bear (conservative · ideal buy zone): [58, 64]
• base (fair · acceptable hold zone): [75, 117]
• bull (optimistic · above the clearly-overvalued line): [130, 145]

13. Key data tables

Clinical and capital-markets milestones

Sources: company announcements, FDA, Summit, Merck collaboration pages, and ASCO materials.

Capital structure and liquidity snapshot

Sources: Akeso 2025 annual report and market data references.

14. Research uncertainties

The largest blind spot is product-level revenue disclosure. Akeso discloses total commercial sales and discusses key drivers, but public materials reviewed here do not provide a clean, up-to-date product-by-product sales bridge for cadonilimab, ivonescimab, and the rest of the portfolio. That makes it harder to separate de-risked franchise value from flagship concentration.

Second, the market-data vendors available in public search snippets show small discrepancies in current price and market capitalization snapshots around the 2026-06-23/24 window. That does not change the investment conclusion, but it means point-estimate multiples should be read as approximate rather than exact to the last decimal.

Third, the global readthrough of HARMONi-6 remains an analytical judgment, not a settled fact. The trial result is real; the debate is how much it says about ex-China populations and the broader first-line NSCLC opportunity set. That uncertainty is central to Akeso’s valuation.

Fourth, some details of the future Summit milestone stream remain contingent on events and therefore are not directly bankable. Public filings verify the structure and headline magnitude, but investors should not treat all milestone numbers as economically equivalent to cash already earned.

15. Sources

Primary company filings and announcements used in this report include Akeso’s 2025 annual report, 2024 annual report, 2024–2025 placing announcements, investor-relations pages, and product/regulatory press releases.

Primary external regulatory and partner sources include Summit’s 10-K, 10-Q and press releases on the Akeso partnership and FDA review, the FDA penpulimab approval page, China NMPA references for ivonescimab, ASCO materials for HARMONi-6, and Merck/Akeso collaboration materials.

Supplementary market and peer context came from Reuters company pages and news coverage, peer annual-result disclosures, market-data references for Akeso and key peers, BioNTech/BMS partnership disclosure, and FX/yield references from CFETS, ChinaBond, and related public market sources.

16. Other tickers mentioned

• 01801.HK: China commercial biologics peer used to benchmark scale, sales multiples, and execution maturity
• ONC.US: Chinese-origin global oncology benchmark showing what a mature commercial engine looks like
• SMMT.US: ex-China ivonescimab mirror asset and the key external validator of Akeso’s flagship economics
• BNTX.US: PD-L1/VEGF-style next-generation IO peer through BNT327 and a major comparator for mechanism-level valuation
• MRK.US: incumbent IO benchmark through pembrolizumab and Akeso’s earlier licensing partner
• 02157.HK: Lepu Biopharma, mentioned as Akeso’s licensee for pucotenlimab in the commercial-stage portfolio

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.